These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15837552)

  • 1. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease.
    Weir MR
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):100S-105S. PubMed ID: 15837552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting renal function in the hypertensive patient: clinical guidelines.
    Bakris GL
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):112S-119S. PubMed ID: 15837554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto K
    Pharmacotherapy; 2009 Sep; 29(9):1061-72. PubMed ID: 19698011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials.
    Segall L; Oprisiu R; Fournier A; Covic A
    J Nephrol; 2008; 21(3):374-83. PubMed ID: 18587726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How early should blood pressure control be achieved for optimal cardiovascular outcomes?
    Weir MR; Zappe D; Orloski LA; Sowers JR
    J Hum Hypertens; 2011 Apr; 25(4):211-7. PubMed ID: 20596060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax).
    Ruilope LM; Segura J
    J Hypertens Suppl; 2006 May; 24(3):S9-12. PubMed ID: 16723864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and management of hypertension in patients with type 2 diabetes.
    Thomas MC; Atkins R
    Intern Med J; 2009 Mar; 39(3):143-9. PubMed ID: 18771428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progression factors in chronic kidney disease. Non-immunological mechanisms].
    Fernández Fresnedo G; Sánchez Plumed J; Arias M; Del Castillo Caba D; López Oliva MO
    Nefrologia; 2009; 29 Suppl 1():16-24. PubMed ID: 19675657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.